JP2020532304A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532304A5 JP2020532304A5 JP2020512821A JP2020512821A JP2020532304A5 JP 2020532304 A5 JP2020532304 A5 JP 2020532304A5 JP 2020512821 A JP2020512821 A JP 2020512821A JP 2020512821 A JP2020512821 A JP 2020512821A JP 2020532304 A5 JP2020532304 A5 JP 2020532304A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- tcr
- seq
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 42
- 108091008874 T cell receptors Proteins 0.000 claims 37
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 37
- 210000004027 cell Anatomy 0.000 claims 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 102000040430 polynucleotide Human genes 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 12
- 239000002157 polynucleotide Substances 0.000 claims 12
- 239000005557 antagonist Substances 0.000 claims 10
- 239000013598 vector Substances 0.000 claims 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims 8
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims 4
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 1
- 102000006390 HLA-B Antigens Human genes 0.000 claims 1
- 108010058607 HLA-B Antigens Proteins 0.000 claims 1
- 102000012215 HSC70 Heat-Shock Proteins Human genes 0.000 claims 1
- 108010036652 HSC70 Heat-Shock Proteins Proteins 0.000 claims 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 claims 1
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 claims 1
- 230000006052 T cell proliferation Effects 0.000 claims 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 1
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 230000003439 radiotherapeutic effect Effects 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 241000701447 unidentified baculovirus Species 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762553957P | 2017-09-04 | 2017-09-04 | |
| US62/553,957 | 2017-09-04 | ||
| PCT/US2018/049397 WO2019046856A1 (en) | 2017-09-04 | 2018-09-04 | T-CELL RECEPTORS THAT BIND TO SPECIFIC PHOSPHOPEPTIDES OF MIXED LINEAR LEUKEMIA (MLL) AND METHODS OF USE THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532304A JP2020532304A (ja) | 2020-11-12 |
| JP2020532304A5 true JP2020532304A5 (https=) | 2021-10-21 |
| JP7387585B2 JP7387585B2 (ja) | 2023-11-28 |
Family
ID=63722758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020512821A Active JP7387585B2 (ja) | 2017-09-04 | 2018-09-04 | 混合系統白血病（ｍｌｌ）特異的ホスホペプチドに結合するｔ細胞受容体およびその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11718658B2 (https=) |
| EP (1) | EP3679062B1 (https=) |
| JP (1) | JP7387585B2 (https=) |
| KR (1) | KR20200052327A (https=) |
| CN (1) | CN111278854A (https=) |
| AU (1) | AU2018326875A1 (https=) |
| CA (1) | CA3073055A1 (https=) |
| MA (1) | MA50084A (https=) |
| SG (1) | SG11202001319QA (https=) |
| WO (1) | WO2019046856A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3073055A1 (en) | 2017-09-04 | 2019-03-07 | Agenus Inc. | T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof |
| WO2020206238A2 (en) * | 2019-04-05 | 2020-10-08 | Rootpath Genomics, Inc. | Compositions and methods for t-cell receptor gene assembly |
| TWI869426B (zh) * | 2019-07-30 | 2025-01-11 | 大學健康網絡 | Ｔ細胞受體及其使用方法 |
| WO2021216738A2 (en) * | 2020-04-21 | 2021-10-28 | Intima Bioscience, Inc. | Compositions and methods of generating an immune response |
| KR102827472B1 (ko) | 2020-04-29 | 2025-07-02 | 삼성디스플레이 주식회사 | 유기 전계 발광 소자 및 유기 전계 발광 소자용 화합물 |
| EP4472742A1 (en) * | 2022-02-03 | 2024-12-11 | University College Cardiff Consultants Limited | Novel t-cell receptor |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5997873A (en) | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
| WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| US5580714A (en) | 1995-03-08 | 1996-12-03 | Celox Laboratories, Inc. | Cryopreservation solution |
| US5935576A (en) | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
| US6017540A (en) | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
| CA2302522C (en) | 1997-08-29 | 2010-08-17 | Antigenics Llc | Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient |
| US5948646A (en) | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
| GB9809658D0 (en) | 1998-05-06 | 1998-07-01 | Celltech Therapeutics Ltd | Biological products |
| PT1104306E (pt) | 1998-08-10 | 2006-05-31 | Antigenics Inc | Composicoes de cpg e adjuvantes de saponina e seus metodos |
| IL127142A0 (en) | 1998-11-19 | 1999-09-22 | Yeda Res & Dev | Immune cells having predefined biological specificity |
| US6194137B1 (en) | 1999-04-13 | 2001-02-27 | Organ Recovery Systems, Inc. | Method of cryopreservation of blood vessels by vitrification |
| WO2000063374A1 (en) | 1999-04-16 | 2000-10-26 | Celltech Therapeutics Limited | Synthetic transmembrane components |
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| DK1234031T3 (en) | 1999-11-30 | 2017-07-03 | Mayo Foundation | B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE |
| IL160359A0 (en) | 2001-08-31 | 2004-07-25 | Avidex Ltd | Soluble t cell receptor |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CA2501870C (en) | 2002-10-09 | 2013-07-02 | Avidex Limited | Single chain recombinant t cell receptors |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| EP1723257B1 (en) | 2004-02-23 | 2019-01-09 | Erasmus University Medical Center Rotterdam | Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling |
| ATE475669T1 (de) | 2004-06-29 | 2010-08-15 | Immunocore Ltd | Einen modifizierten t-zellen-rezeptor exprimierende zellen |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| GB0712670D0 (en) | 2007-06-29 | 2007-08-08 | King S College London | Isolated peptides and uses thereof |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| JP5465720B2 (ja) | 2008-07-08 | 2014-04-09 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| AU2009290544B2 (en) | 2008-09-12 | 2015-07-16 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP2486049A1 (en) | 2009-10-06 | 2012-08-15 | The Board Of Trustees Of The UniversityOf Illinois | Human single-chain t cell receptors |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| US20130202623A1 (en) | 2010-02-16 | 2013-08-08 | Nicolas Chomont | Pd-1 modulation and uses thereof for modulating hiv replication |
| EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| EP2576614A4 (en) * | 2010-05-24 | 2013-11-13 | Phosimmune Inc | CLASS I-MHC PHOSPHOPEPTIDES FOR CANCER IMMUNOTHERAPY AND DIAGNOSIS |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| CA2840018C (en) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| US8920075B2 (en) | 2011-09-01 | 2014-12-30 | Halo Maritime Defense Systems, Inc. | Marine barrier and gate |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| CA3285826A1 (en) | 2012-02-22 | 2026-03-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| CN111499755A (zh) | 2012-08-03 | 2020-08-07 | 丹娜法伯癌症研究院 | 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法 |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| US20160145355A1 (en) | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| AU2014301777B2 (en) * | 2013-06-26 | 2017-03-30 | Xlifesc, Ltd. | High-stability T-cell receptor and preparation method and application thereof |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| US10077305B2 (en) | 2013-09-10 | 2018-09-18 | Medimmune Limited | Antibodies against PD-1 and uses thereof |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| EP3060581A4 (en) | 2013-10-25 | 2017-06-07 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
| CN104558177B (zh) | 2013-10-25 | 2020-02-18 | 苏州思坦维生物技术股份有限公司 | 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途 |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| PL3094351T3 (pl) | 2014-01-15 | 2022-06-27 | Kadmon Corporation, Llc | Środki immunomodulujące |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| BR112016014952A2 (pt) | 2014-02-10 | 2017-09-19 | Merck Patent Gmbh | Inibição direcionada de tgfbeta |
| US10934346B2 (en) | 2014-02-14 | 2021-03-02 | Bellicum Pharmaceuticals, Inc. | Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12 |
| EP3137100B1 (en) * | 2014-04-15 | 2023-12-20 | University Of Virginia Patent Foundation | Isolated t cell receptors and methods of use therefor |
| JP6666905B2 (ja) | 2014-05-29 | 2020-03-18 | スプリング バイオサイエンス コーポレーション | Ｐｄ−ｌ１抗体及びその使用 |
| WO2015195163A1 (en) | 2014-06-20 | 2015-12-23 | R-Pharm Overseas, Inc. | Pd-l1 antagonist fully human antibody |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| CN105330740B (zh) | 2014-07-30 | 2018-08-17 | 珠海市丽珠单抗生物技术有限公司 | 抗pd-1抗体及其应用 |
| KR102357893B1 (ko) | 2014-08-05 | 2022-02-04 | 맵퀘스트 에스아 | Pd-1 에 결합하는 면역학적 시약 |
| DK3186283T3 (da) | 2014-08-29 | 2020-03-02 | Hoffmann La Roche | Kombinationsbehandling med tumormålrettede IL-2- immuncytokinervarianter og antistoffer mod humant PD-L1 |
| CA2996887A1 (en) * | 2015-09-11 | 2017-03-16 | Agenus Inc. | Engineered host cells and methods of use thereof |
| CA3073055A1 (en) | 2017-09-04 | 2019-03-07 | Agenus Inc. | T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof |
-
2018
- 2018-09-04 CA CA3073055A patent/CA3073055A1/en active Pending
- 2018-09-04 EP EP18782236.6A patent/EP3679062B1/en active Active
- 2018-09-04 AU AU2018326875A patent/AU2018326875A1/en not_active Abandoned
- 2018-09-04 KR KR1020207009786A patent/KR20200052327A/ko not_active Ceased
- 2018-09-04 MA MA050084A patent/MA50084A/fr unknown
- 2018-09-04 WO PCT/US2018/049397 patent/WO2019046856A1/en not_active Ceased
- 2018-09-04 CN CN201880069966.7A patent/CN111278854A/zh active Pending
- 2018-09-04 SG SG11202001319QA patent/SG11202001319QA/en unknown
- 2018-09-04 JP JP2020512821A patent/JP7387585B2/ja active Active
-
2020
- 2020-03-03 US US16/807,742 patent/US11718658B2/en active Active
-
2023
- 2023-06-23 US US18/340,600 patent/US12391741B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020532304A5 (https=) | ||
| JP2020503883A5 (https=) | ||
| Martin-Liberal et al. | The expanding role of immunotherapy | |
| AU2018250336B2 (en) | Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods | |
| Saibil et al. | Targeting T cell activation in immuno-oncology | |
| CN112703012A (zh) | 治疗癌症的方法 | |
| AU2015307316A1 (en) | CD94/NKG2A and/or CD94/NKG2B antibody, vaccine combinations | |
| CN102753195A (zh) | 用于增强抗肿瘤抗体疗法的方法 | |
| RS63561B1 (sr) | Kompozicija za lečenje raka | |
| US11951131B2 (en) | Anti-SLAMF7 chimeric antigen receptors | |
| WO2018102786A1 (en) | Methods for modulation of car-t cells | |
| CN110719799A (zh) | Cd39和cd103在鉴定用于癌症治疗的人肿瘤反应性t细胞中的应用 | |
| JP2019520034A5 (https=) | ||
| US20210069246A1 (en) | Combination therapy using adoptive cell therapy and checkpoint inhibitor | |
| US12583910B2 (en) | T cell antigen receptor, multimeric complex thereof, and preparation method therefor and use thereof | |
| JP2024144409A (ja) | がん幹細胞特異的抗体 | |
| Ravindranath et al. | The monospecificity of novel anti-HLA-E monoclonal antibodies enables reliable immunodiagnosis, immunomodulation of HLA-E, and upregulation of CD8+ T lymphocytes | |
| Britsch et al. | Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selectively eliminate carcinoma cells | |
| EP4093759A1 (en) | Hbv specific tcr library and its use as personalised medicine | |
| Raguz et al. | Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment | |
| CN116496411A (zh) | Afp特异性t细胞受体及其用途 | |
| US20200148758A1 (en) | Therapeutic combinations comprising eosinophil-depleting antibodies and uses thereof | |
| US20240424098A1 (en) | Modified immune cells and methods of use thereof | |
| van Wijngaarden | Repurposing anti-CMV T cells to eliminate cancer cells; an alternate form of cancer immunotherapy | |
| Subklewe | Current status of immunotherapy in acute myeloid leukemia |